Max Access Solutions is our innovative, patient-centered model for delivering cancer treatment to those in need. Through the program, launched in 2017, we connect people facing cancer in countries where treatment is not locally available to high-impact medicines, qualified medical professionals and essential support services.
This work is made possible through partnerships with local physicians, ministries of health, other non-governmental organizations, patient organizations, and medicine manufacturers. Our partner physicians play a vital role in receiving the medication at the local level, enrolling patients into the program, and providing the individual care each patient needs.
Max Access Solutions is meant to bridge access to treatment in underserved areas, with a focus on low- and middle-income countries, until local access channels can be put in place.
- 37K+
patients provided access to medication and/or support services each year
- 83
countries where medication access and/or support services are provided
- 16
cancer medicines provided
Our Cancer Programs
For over 25 years, we’ve developed our cancer programs and expanded our partnerships to reach cancer patients in more than 80 low- and middle-income countries. We now offer a wide portfolio of lifesaving medications for 13 disease areas and growing.
“The access to drugs, at no cost, has not only helped me financially but also enhanced my overall well-being. This has enabled me to sustain my occupation as a farmer, which demands immense endurance and physical strength. As a patient facing financial constraints, the provision of such vital medication is invaluable, and I cannot express enough gratitude to The Max Foundation, [the pharmaceutical company], and my treating physicians for facilitating access to this treatment.”
– Serali, a farmer, father, and grandfather from Nepal living with chronic myeloid leukemia
Latest Developments
The Max Foundation (Max) and the International PNH Interest Group (IPIG) Announce Collaboration to Improve Care and Management for People Living with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Low-Resource Countries
IPIG joins Max’s Humanitarian Partnership for Access to Critical Treatments (Humanitarian PACT) and will provide medical education and training on PNH care and management Max will provide access to innovative treatment as part of the multi-stakeholder collaboration focused on eradicating survival disparities in 53 low-resource countries People living with this rare blood disease require frequent….
The Max Foundation (Max) Expands Collaboration with Novartis to Include Access to Innovative Treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH)
Max to immediately begin process to provide humanitarian access for Fabhalta® (iptacopan) in collaboration with its network of partner hematologists across 53 countries People living with the rare blood disease in low-middle income countries require frequent blood transfusions, experience debilitating symptoms of fatigue and without treatment may progress to more serious life-threatening diseases The Max….
Overcoming Barriers to Access
Improving health outcomes for people living with cancer is about more than medication. We provide access to psychosocial support, transportation assistance, adherence monitoring, and more to ensure patient needs are handled individually and holistically.
Learn More
2023 M&E Report
Download Report